$4.21
Precision BioSciences
Performance
Dividends
-12.11%
1W
1M
YTD
1Y
3Y
16/36
Growth Score
8/36
Dividend Score
Valuation
PE Ratio
-1.79
PS Ratio
0.92
RSI
-
0
PEG Ratio
0
0
PRG Ratio
3.6
PDG Ratio
0
Growth
394%341%0-79%349%
45%112%-10604%33%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
0
Rule of 40
21.1%
3
Gross Margin
100%
3
Current Ratio
6.62
Return on Assets
-17.67%
Return on Equity
-35.85%
Return on inv. Capital
-38.88%
Institutional Holder
9.217.09008.337.249
55163
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 68.70M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 7.17M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 68.70M
2018
2019
2020
2021
2022
2023
2024
6
Events
DTIL
Precision BioSciences
in 286 days
before market open
Earnings per Share is expected with - and revenue with - .
DTIL
Precision BioSciences
in 236 days
before market open
Earnings per Share is expected with - and revenue with - .
DTIL
Precision BioSciences
in 95 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
28.03.2019
MaketCap
46.95M
Country
US
CEO
Mr. Michael Amoroso
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Updated 25.06.2025